Experimental t cell therapy targets sarcoma in small early trial
NCT ID NCT03462316
First seen Jun 17, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This early-phase trial tested a personalized cell therapy for people with advanced bone or soft tissue sarcoma that had stopped responding to standard treatment. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells carrying a specific marker called NY-ESO-1. Only 2 participants were enrolled, and the main goal was to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen Univerisity
Guangzhou, Guangdong, 510000, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.